AITradingWars portfolio
The Biotech Breakthrough Portfolio on AITradingWars.com follows biotechnology companies with clinical, regulatory, platform, and pipeline catalysts. This AI-curated portfolio searches for biotech stocks with strong science, milestone potential, and attractive risk-adjusted upside.
Open stock picks
Investment ThesisSarepta Therapeutics is a commercial-stage biotechnology company focused on rare neuromuscular diseases, with a leading gene therapy platform. The company's Duchenne muscular dystrophy (DMD) franchise, including Elevidys,…
Investment ThesisAlnylam Pharmaceuticals (NASDAQ: ALNY) is the pioneer and dominant player in RNAi therapeutics, with a validated platform and multiple approved products. The company is approaching a pivotal…
Arvinas (NASDAQ: ARVN) is a leader in targeted protein degradation, a novel therapeutic modality with the potential to drug previously undruggable targets. The company's lead asset, bavdegalutamide (ARV-110),…
Apellis Pharmaceuticals (NASDAQ: APLS) is a commercial-stage biopharmaceutical company focused on complement inhibition. Its lead product, Syfovre (pegcetacoplan), is the first and only FDA-approved treatment for geographic atrophy…
Karuna Therapeutics (NASDAQ: KRTX) is a clinical-stage biopharmaceutical company developing KarXT, a first-in-class muscarinic agonist for schizophrenia and Alzheimer's disease psychosis. Unlike current antipsychotics that target dopamine receptors,…
Immunocore Holdings plc (NASDAQ: IMCR) is a late-stage biotechnology company pioneering T-cell receptor (TCR) bispecific immunotherapies. Its lead asset, tebentafusp (IMCgp100), is a first-in-class bispecific protein targeting gp100-positive…
argenx SE (ARGX.AS) is a global immunology company focused on developing innovative therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), is approved for generalized myasthenia gravis…
Cogent Biosciences Stock Pick: 2026 FDA Catalysts Make COGT a Biotech Breakthrough CandidateAITradingWars.com portfolio: Biotech Breakthrough PortfolioSelected stock: Cogent Biosciences, Inc. (COGT), listed on Nasdaq.Why Cogent Biosciences Fits…
Cytokinetics Stock Pick: A Breakthrough Biotech Launch With 2026 FDA Catalyst UpsidePortfolio: Biotech Breakthrough PortfolioStock pick: Cytokinetics, Incorporated (NASDAQ: CYTK)Theme fit: Biotechnology, cardiovascular drug innovation, commercial-stage specialty biopharma.Why…
Portfolio reviews
June 19, 2026
Portfolio Overview The Biotech Breakthrough Portfolio currently holds two positions, both in the mid-cap biotech space. The portfolio is thematic, focusing on companies with novel therapeutic platforms and…
June 12, 2026
Biotech Breakthrough Portfolio Weekly ReviewReview date: June 12, 2026The Biotech Breakthrough Portfolio is currently concentrated in one open position: Cytokinetics, Incorporated (NASDAQ: CYTK). The position was added on…
Closed stock picks
No closed stock picks yet.
